{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:26Z","timestamp":1792714286669,"version":"4.5.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bbi.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:17:32Z","timestamp":1728505052000},"page":"725-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome"],"prefix":"10.1016","volume":"123","author":[{"given":"Brinkley A.","family":"Morse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Motovilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Michael Brode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Michael Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-3591","authenticated-orcid":false,"given":"Esther","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","article-title":"Intravenous immunoglobulin treatment in multiple sclerosis effect on relapses","volume":"50","author":"Achiron","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.bbi.2024.10.006_b0010","first-page":"1","article-title":"Long covid in adults: United states, 2022","volume":"480","author":"Adjaye-Gbewonyo","year":"2023","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.bbi.2024.10.006_b0015","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.biopha.2017.06.001","article-title":"Effect of intravenous immunoglobulin on th1 and th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (rpl)","volume":"92","author":"Ahmadi","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"7354","key":"10.1016\/j.bbi.2024.10.006_b0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel th2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2024.10.006_b0025","unstructured":"Arumugham, V.B., Rayi, A., 2022, 7. Intravenous immunoglobulin (ivig). StatPearls. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554446\/http:\/\/www.pubmedcentral.nih.gov\/ articlerender.fcgi?artid=PMC4808809."},{"issue":"4","key":"10.1016\/j.bbi.2024.10.006_b0030","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3476(05)80707-3","article-title":"Treatment of kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin","volume":"117","author":"Barron","year":"1990","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.bbi.2024.10.006_b0035","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbi.2024.10.006_b0040","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type i ifns in patients with life-threatening covid-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbi.2024.10.006_b0045","unstructured":"Beecham, G.B., Tackling, G., 2022, 7. Peripheral line placement. StatPearls. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539795\/."},{"key":"10.1016\/j.bbi.2024.10.006_b0050","doi-asserted-by":"crossref","unstructured":"Behera, A., Guru, S., 2020, 8. Intravenous immunoglobulin-associated elevation of liver enzymes in neurological autoimmune disorder: A case series. Cureus, 12. Retrieved from .ncbi.nlm.nih.gov\/32983715\/ DOI: 10.7759\/CUREUS.10020.","DOI":"10.7759\/cureus.10020"},{"key":"10.1016\/j.bbi.2024.10.006_b0055","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/ACI.0b013e32834c22da","article-title":"Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose","volume":"11","author":"Berger","year":"2011","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.638816","article-title":"Individualizing therapy in CIDP: a mini-review comparing the pharmacokinetics of Ig with SCIg and IVIG","volume":"12","author":"Beydoun","year":"2021","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.bbi.2024.10.006_b0065","article-title":"Persistent relapsing immune thrombocytopenia following covid-19 infection","volume":"14","author":"Boehm","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.006_b0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/cei.12043","article-title":"Altered functional b cell subset populations in patients with chronic fatigue syndrome compared to healthy controls","volume":"172","author":"Bradley","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"28","key":"10.1016\/j.bbi.2024.10.006_b0075","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1073\/pnas.1522730113","article-title":"Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins","volume":"113","author":"Br\u00e4ndle","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbi.2024.10.006_bib802","doi-asserted-by":"crossref","unstructured":"Brannagan, T. H., III, Nagle, K. J., Lange, D. J., and Rowland, L. P. (1996). Complications of intravenous immune globulin treatment in neurologic disease. Neurology, 47(3), 674\u2013677. https:\/\/doi.org\/10.1212\/WNL47.3.674.","DOI":"10.1212\/WNL.47.3.674"},{"issue":"11","key":"10.1016\/j.bbi.2024.10.006_b0080","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/healthcare9111546","article-title":"Back to the future? immunoglobulin therapy for myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"9","author":"Brownlie","year":"2021","journal-title":"Healthcare"},{"issue":"6","key":"10.1016\/j.bbi.2024.10.006_b0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in guillain-barr\u00e9 syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"key":"10.1016\/j.bbi.2024.10.006_b0090","unstructured":"Burnouf, T., 2012, 7. Plasma fractionation. ISBT Science Series, 7, 62-67. Retrieved from https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1751-2824.2012.01557.xhttps:\/\/ onlinelibrary .wiley .com\/doi\/abs\/10 .1111\/j .1751 -2824 .2012 .01557 .xhttps:\/\/ onlinelibrary.wiley.com\/doi\/10.1111\/j.1751-2824.2012.01557.x DOI: 10.1111\/J.17512824.2012.01557.X."},{"key":"10.1016\/j.bbi.2024.10.006_b0095","doi-asserted-by":"crossref","unstructured":"Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Li, T., 2020. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. In Open forum infectious diseases (Vol. 7, p. ofaa102).","DOI":"10.1093\/ofid\/ofaa102"},{"key":"10.1016\/j.bbi.2024.10.006_b0100","doi-asserted-by":"crossref","unstructured":"Cervia-Hasler, C., Brun\u0308ingk, S.C., Hoch, T., Fan, B., Muzio, G., Thompson, R.C., others 2024. Persistent complement dysregulation with signs of thrombo-ceinflammation in active long covid. Science, 383(6680), eadg7942.","DOI":"10.1126\/science.adg7942"},{"key":"10.1016\/j.bbi.2024.10.006_b0105","doi-asserted-by":"crossref","unstructured":"Chapel, H.M., 1999. Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. iuis committee on primary immunodeficiency disease. international union of immunological societies. Clinical and experimental immunology, 118 Suppl 1, 29-34. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/10540201\/ DOI: 10.1046\/J.13652249.1999.00000.X.","DOI":"10.1046\/j.1365-2249.1999.00000.x"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.006_b0110","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.006_b0115","first-page":"1503709","article-title":"Treatments for severe cutaneous adverse reactions","volume":"2017","author":"Cho","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1529-8027.2011.00340.x","article-title":"The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin","volume":"16","author":"Cocito","year":"2011","journal-title":"Journal of the Peripheral Nervous System: JPNS"},{"key":"10.1016\/j.bbi.2024.10.006_b0125","doi-asserted-by":"crossref","unstructured":"Comi, G., Bar-Or, A., Lassmann, H., Uccelli, A., Hartung, H.-P., Montalban, X., of the 27th Annual Meeting of the European Charcot Foundation, E.P., 2021. Role of b cells in multiple sclerosis and related disorders. Annals of neurology, 89(1), 13\u201323.","DOI":"10.1002\/ana.25927"},{"key":"10.1016\/j.bbi.2024.10.006_b0130","doi-asserted-by":"crossref","unstructured":"Cuesta, H., Menyawi, I. E., Hubsch, A., Hoefferer, L., Mielke, O., Gabriel, S., Shebl, A., 2022, 9. Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations. Transfusion, 62, 1894. Retrieved from \/pmc\/articles\/PMC9545798\/\/pmc\/articles\/PMC9545798\/?report=abstracthttps:\/\/www.ncbi.nlm.nih.gov\/ pmc\/articles\/PMC9545798\/ DOI: 10.1111\/TRF.17028.","DOI":"10.1111\/trf.17028"},{"key":"10.1016\/j.bbi.2024.10.006_b0135","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of fcrn in neuro-immunotherapies: from igg catabolism, fcgrt gene polymorphisms, ivig dosing and efficiency to specific fcrn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bbi.2024.10.006_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact","volume":"38","author":"Davis","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbi.2024.10.006_b0145","doi-asserted-by":"crossref","unstructured":"Davis, H.E., McCorkell, L., Vogel, J.M., et al., 2023. Long COVID: Major findings, mechanisms, and recommendations. Nature Reviews Microbiology, 21, 133\u2013146. Retrieved from https:\/\/doi.org\/10.1038\/s41579-022-00846-2 DOI: 10.1038\/s41579-022-00846-2.","DOI":"10.1038\/s41579-022-00846-2"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.006_b0150","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1200\/OP.20.00312","article-title":"Changes in intravenous immunoglobulin usage for hypogammaglobulinemia after implementation of a stewardship program","volume":"17","author":"Derman","year":"2021","journal-title":"JCO Oncology Practice"},{"key":"10.1016\/j.bbi.2024.10.006_b0155","unstructured":"Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS\u201d National Library of Medicine, ClinicalTrials.gov , https:\/\/clinicaltrials.gov\/study\/NCT06524739. Accessed 6 Sept. 2024."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.006_b0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00003246-200001000-00002","article-title":"Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins","volume":"28","author":"Douzinas","year":"2000","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bbi.2024.10.006_b0165","unstructured":"Doyle, G.R., et al., n.d. 8.2: Intravenous fluid therapy. https:\/\/opentextbc.ca\/clinicalskills\/ chapter\/intravenous-therapy-peripheral-and-central-venous-catheters\/. ([Online; accessed May 2, 2023])."},{"key":"10.1016\/j.bbi.2024.10.006_b0170","doi-asserted-by":"crossref","unstructured":"Duff, C., Ochoa, D., Riley, P., Murphy, E., Zampelli, A., 2013. Importance of ancillary supplies for subcutaneous immunoglobulin infusion: management of the local infusion site. Journal of infusion nursing: the official publication of the Infusion Nurses Society, 36, 384-390. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/24202117\/ DOI: 10.1097\/NAN.0000000000000009.","DOI":"10.1097\/NAN.0000000000000009"},{"key":"10.1016\/j.bbi.2024.10.006_b0175","doi-asserted-by":"crossref","unstructured":"Eftimov, F., Winer, J.B., Vermeulen, M., de Haan, R., van Schaik, I.N., 2013. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews(12).","DOI":"10.1002\/14651858.CD001797.pub3"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0180","first-page":"715","article-title":"Expansion of cd4+ cd25+ regulatory t cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"9052","key":"10.1016\/j.bbi.2024.10.006_b0185","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebocontrolled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.006_b0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.bbi.2024.10.006_b0195","doi-asserted-by":"crossref","first-page":"e0129898","DOI":"10.1371\/journal.pone.0129898","article-title":"B-lymphocyte depletion in myalgic encephalopathy\/chronic fatigue syndrome. an open-label phase ii study with rituximab maintenance treatment","volume":"10","author":"Fluge","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbi.2024.10.006_b0200","unstructured":"for Disease Control, C., & Prevention. (n.d.). Long covid or post-covid conditions. Retrieved from https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects\/index.html."},{"issue":"8373","key":"10.1016\/j.bbi.2024.10.006_b0205","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"323","author":"Gajdos","year":"1984","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.006_b0210","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other cd20+ b-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1\u20132","key":"10.1016\/j.bbi.2024.10.006_b0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jneuroim.2004.01.010","article-title":"Prior poliomyelitis\u2014ivig treatment reduces proinflammatory cytokine production","volume":"150","author":"Gonzalez","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0220","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Jun 8). Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbi.2024.10.006_b0225","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1191\/1352458505ms1224oa","article-title":"Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis-results of a retrospective multicenter observational study over five years","volume":"11","author":"Haas","year":"2005","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.bbi.2024.10.006_b0230","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00421-011-1975-3","article-title":"Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects","volume":"112","author":"Harbo","year":"2012","journal-title":"Eur. J. Appl. Physiol."},{"key":"10.1016\/j.bbi.2024.10.006_b0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-3002-0","article-title":"Advances in the understanding of the mechanism of action of ivig","volume":"255","author":"Hartung","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbi.2024.10.006_b0240","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2008.06.002","article-title":"Intravenous immunoglobulins: evolution of commercial ivig preparations","volume":"28","author":"Hooper","year":"2008","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.bbi.2024.10.006_b0245","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10616-017-0176-2","article-title":"Anti-inflammatory intravenous immunoglobulin (ivig) suppresses homeostatic proliferation of b cells","volume":"70","author":"Hori","year":"2018","journal-title":"Cytotechnology"},{"key":"10.1016\/j.bbi.2024.10.006_b0250","doi-asserted-by":"crossref","unstructured":"Hosseini, K.M., Ghasemzadeh, M., 2016, 9. Implementation of plasma fractionation in biological medicines production. Iranian journal of biotechnology, 14, 213-220. Retrieved from https:\/\/ pubmed.ncbi.nlm.nih.gov\/28959338\/ DOI: 10.15171\/IJB.1401.","DOI":"10.15171\/ijb.1401"},{"issue":"10223","key":"10.1016\/j.bbi.2024.10.006_b0255","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, china","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0260","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ice study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"The Lancet Neurology"},{"issue":"8232","key":"10.1016\/j.bbi.2024.10.006_b0265","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"317","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2024.10.006_b0270","unstructured":"Immunotherapy for neurological post-acute sequelae of sars-cov-2. (2023). ClinicalTrials.gov Identifier NCT05350774. (Accessed February 6, 2024)."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_bib801","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.clim.2015.05.003","article-title":"Intravenous igg (ivig) and subcu- taneous igg (scig) preparations have comparable inhibitory effect on t cell activation, which is not dependent on igg sialylation, monocytes or b cells","volume":"160","author":"Issekutz","year":"2015","journal-title":"Clinical immunology"},{"key":"10.1016\/j.bbi.2024.10.006_b0275","first-page":"200","article-title":"Agammaglobulinemia","volume":"66","author":"Janeway","year":"1953","journal-title":"Trans. Assoc. Am. Phy"},{"key":"10.1016\/j.bbi.2024.10.006_b0280","doi-asserted-by":"crossref","unstructured":"Jayne, D.R., Chapel, H., Adu, D., Misbah, S., O\u2019Donoghue, D., Scott, D., Lockwood, C.M., 2000. Intravenous immunoglobulin for anca-associated systemic vasculitis with persistent disease activity. QJM : monthly journal of the Association of Physicians, 93, 433-439. Retrieved from https:\/\/ pubmed.ncbi.nlm.nih.gov\/10874052\/ DOI: 10.1093\/QJMED\/93.7.433.","DOI":"10.1093\/qjmed\/93.7.433"},{"issue":"11","key":"10.1016\/j.bbi.2024.10.006_b0285","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for igg catabolism is the beta2-microglobulin containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbi.2024.10.006_b0290","doi-asserted-by":"crossref","unstructured":"Katz, U., Achiron, A., Sherer, Y., Shoenfeld, Y., 2007, 3. Safety of intravenous immunoglobulin (ivig) therapy. Autoimmunity reviews, 6, 257-259. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/ 17317619\/ DOI: 10.1016\/J.AUTREV.2006.08.011.","DOI":"10.1016\/j.autrev.2006.08.011"},{"key":"10.1016\/j.bbi.2024.10.006_b0295","unstructured":"Kaur, H., Betances, E.M., Perera, T.B., 2022, 5. Aseptic meningitis. StatPearls. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557412\/http:\/\/www.pubmedcentral.nih.gov\/ articlerender.fcgi?artid=PMC4718237."},{"key":"10.1016\/j.bbi.2024.10.006_b0300","doi-asserted-by":"crossref","unstructured":"Kemmotsu, Y., Nakayama, T., Matsuura, H., et al., 2011. Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with kawasaki disease. Pediatric Rheumatology, 9, 28. Retrieved from https:\/\/doi.org\/10.1186\/1546-0096-9-28 DOI: 10.1186\/1546-0096-9-28.","DOI":"10.1186\/1546-0096-9-28"},{"key":"10.1016\/j.bbi.2024.10.006_b0305","doi-asserted-by":"crossref","unstructured":"Kieseier, B.C., Tani, M., Mahad, D., Oka, N., Ho, T., Woodroofe, N., Hartung, H.-P., 2002. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for ip-10. Brain, 125(4), 823\u2013834.","DOI":"10.1093\/brain\/awf070"},{"key":"10.1016\/j.bbi.2024.10.006_b0310","doi-asserted-by":"crossref","unstructured":"Kissel, M., Phoon, C.K., Kahn, P.J., 2015, 5. Hypertension during intravenous immune globulin infusion for kawasaki\u2019s disease: An underreported phenomenon? Clinical Pediatrics, 54, 491-493. Retrieved from https:\/\/journals.sagepub.com\/doi\/10.1177\/0009922814536776 DOI: 10.1177\/0009922814536776\/ASSET\/0009922814536776.FP.PNGV 03.","DOI":"10.1177\/0009922814536776"},{"key":"10.1016\/j.bbi.2024.10.006_b0315","doi-asserted-by":"crossref","unstructured":"Klein, J., Wood, J., Jaycox, J., et al., 2023. Distinguishing features of long covid identified through immune profiling. Nature, 623, 139\u2013148. Retrieved from https:\/\/doi.org\/10.1038\/s41586-023 -06651-y DOI: 10.1038\/s41586-023-06651-y.","DOI":"10.1038\/s41586-023-06651-y"},{"key":"10.1016\/j.bbi.2024.10.006_b0320","doi-asserted-by":"crossref","unstructured":"Kobayashi, R.H., Rigas, M.T., 2022, 9. Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations. American Journal of Health-System Pharmacy: AJHP, 79, 1415. Retrieved from \/pmc\/articles\/PMC9389421\/\/pmc\/articles\/PMC9389421\/?report=abstracthttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9389421\/ DOI: 10.1093\/AJHP\/ZXAC139.","DOI":"10.1093\/ajhp\/zxac139"},{"key":"10.1016\/j.bbi.2024.10.006_b0325","doi-asserted-by":"crossref","unstructured":"Kobrynski, L., 2012. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics: targets therapy, 6, 277-287. Retrieved from https:\/\/ pubmed.ncbi.nlm.nih.gov\/22956859\/ DOI: 10.2147\/BTT.S25188.","DOI":"10.2147\/BTT.S25188"},{"issue":"8","key":"10.1016\/j.bbi.2024.10.006_b0330","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1172\/JCI118990","article-title":"Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome","volume":"98","author":"Konstantinov","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bbi.2024.10.006_b0335","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1189\/jlb.3VMA0315-078R","article-title":"Intravenous immunoglobulin skews macrophages to an anti-inflammatory, il-10-producing activation state","volume":"98","author":"Kozicky","year":"2015","journal-title":"Journal of Leucocyte Biology"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0340","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","article-title":"In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations\u2013a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases","volume":"12","author":"Krause","year":"2002","journal-title":"Transfus. Med."},{"key":"10.1016\/j.bbi.2024.10.006_b0345","doi-asserted-by":"crossref","unstructured":"Kretowska-Grunwald, A., Krawczuk-Rybak, M., Sawicka-Zukowska, M., 2022, 7. Intravenous immunoglobulin-induced aseptic meningitis-a narrative review of the diagnostic process, pathogenesis, preventative measures and treatment. Journal of clinical medicine, 11. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/35806861\/ DOI: 10.3390\/JCM11133571.","DOI":"10.3390\/jcm11133571"},{"key":"10.1016\/j.bbi.2024.10.006_b0350","doi-asserted-by":"crossref","unstructured":"Lai, C.-C., Chen, W.-C., Chen, C.-Y., Wei, Y.-F., 2022. The effect of intravenous immunoglobulins on the outcomes of patients with covid-19: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Anti-infective Therapy, 20 (10), 1333\u20131340.","DOI":"10.1080\/14787210.2022.2098112"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.006_b0355","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1196\/annals.1423.044","article-title":"Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members baff and april","volume":"1110","author":"Le Pottier","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbi.2024.10.006_b0360","doi-asserted-by":"crossref","unstructured":"Lee, Y.J., Jae, U.S., Lee, J., Kim, K., Won, S.K., Jin, S.A., Won, K.K., 2007. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. Journal of Korean medical science, 22, 758-761. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/ 17728525\/ DOI: 10.3346\/JKMS.2007.22.4.758.","DOI":"10.3346\/jkms.2007.22.4.758"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.006_b0365","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine"},{"issue":"7","key":"10.1016\/j.bbi.2024.10.006_b0370","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1093\/brain\/awac151","article-title":"Neurovascular injury with complement activation and inflammation in covid-19","volume":"145","author":"Lee","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.bbi.2024.10.006_b0375","first-page":"1","article-title":"Intravenous immunoglobulin as the rescue treatment in nmosd patients","author":"Lin","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbi.2024.10.006_b0380","doi-asserted-by":"crossref","unstructured":"Liu, X., Zhang, Y., Lu, L., Li, X., Wu, Y., Yang, Y., Cao, W., 2023. Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe covid-19: An updated systematic review and meta-analysis. Frontiers in Immunology, 14 , 1116738.","DOI":"10.3389\/fimmu.2023.1116738"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.006_b0385","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0002-9343(90)90173-B","article-title":"A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome","volume":"89","author":"Lloyd","year":"1990","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0390","doi-asserted-by":"crossref","first-page":"e210830","DOI":"10.1001\/jamanetworkopen.2021.0830","article-title":"Sequelae in adults at 6 months after covid-19 infection","volume":"4","author":"Logue","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0395","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy","volume":"11","author":"Lun\u0308emann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbi.2024.10.006_b0400","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Efficacy of intravenous immunoglobulin in neurological diseases","volume":"13","author":"Lun\u0308emann","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.006_b0405","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaci.2010.12.1102","article-title":"Inhibition of differentiation, amplification, and function of human th17 cells by intravenous immunoglobulin","volume":"127","author":"Maddur","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.bbi.2024.10.006_b0410","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.it.2017.08.008","article-title":"Circulating normal igg as stimulator of regulatory t cells: lessons from intravenous immunoglobulin","volume":"38","author":"Maddur","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0415","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12016-019-08746-9","article-title":"Natural antibodies: from first-line defense against pathogens to perpetual immune homeostasis","volume":"58","author":"Maddur","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.bbi.2024.10.006_b0420","doi-asserted-by":"crossref","unstructured":"Marcec, R., Dodig, V. M., Radanovic, I., Likic, R., 2022. Intravenous immunoglobulin (ivig) therapy in hospitalised adult covid-19 patients: A systematic review and meta-analysis. Reviews in Medical Virology, 32 (6), e2397.","DOI":"10.1002\/rmv.2397"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.006_b0425","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulinassociated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.006_b0430","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/biomedicines11010180","article-title":"Converging evidence of similar symptomatology of me\/cfs and pasc indicating multisystemic dyshomeostasis","volume":"11","author":"Marks","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbi.2024.10.006_b0435","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jns.2017.04.039","article-title":"Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs","volume":"378","author":"Markvardsen","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbi.2024.10.006_b0440","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, C., Wallenhorst, C., van Nunen, S., 2021, 11. Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study. Clinical and Experimental Immunology, 206, 384-394. Retrieved from https:\/\/academic.oup.com\/cei\/article\/206\/3\/ 384\/6454223 DOI: 10.1111\/CEI.13665.","DOI":"10.1111\/cei.13665"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.006_b0445","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Mart\u00ednez","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.bbi.2024.10.006_b0450","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.jaci.2012.02.050","article-title":"Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3\u2013positive regulatory t cells","volume":"129","author":"Massoud","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.bbi.2024.10.006_b0455","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaci.2013.09.029","article-title":"Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory t cells","volume":"133","author":"Massoud","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0460","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41590-021-01104-y","article-title":"Pathological sequelae of long-haul covid","volume":"23","author":"Mehandru","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0465","doi-asserted-by":"crossref","unstructured":"Melamed, E., Rydberg, L., Ambrose, A., Bhavaraju-Sanka, R., Fine, J., Fleming, T., VerduzcoGutierrez, M., 2023, Mar 29. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of neurologic sequelae in patients with post-acute sequelae of sarscov-2 infection (pasc). PM & R. (Epub ahead of print) DOI: 10.1002\/pmrj.12976.","DOI":"10.1002\/pmrj.12976"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0470","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/cei.12749","article-title":"Extended b cell phenotype in patients with myalgic encephalomyelitis\/chronic fatigue syndrome: a cross-sectional study","volume":"184","author":"Mensah","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.bbi.2024.10.006_b0475","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jns.12302","article-title":"Efficacy and safety of ivig in cidp: combined data of the prima and path studies","volume":"24","author":"Merkies","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbi.2024.10.006_b0480","doi-asserted-by":"crossref","unstructured":"Misbah, S.A., Chapel, H.M., 1993, 10. Adverse effects of intravenous immunoglobulin. Drug Safety, 9, 254-262. Retrieved from https:\/\/link.springer.com\/article\/10.2165\/00002018 -199309040-00003 DOI: 10.2165\/00002018-199309040-00003\/METRICS.","DOI":"10.2165\/00002018-199309040-00003"},{"key":"10.1016\/j.bbi.2024.10.006_b0485","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12026-014-8599-8","article-title":"Intravenous immunoglobulin replacement therapy in common variable immunodeficiency induces b cell depletion through differentiation into apoptosis-prone cd21 low b cells","volume":"60","author":"Mitrevski","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bbi.2024.10.006_b0490","unstructured":"Mulcahy, A.W., Whaley, C., Tebeka, M., Schwarm, D., Edenfield, N., Becerra-Ornelas, A., 2022, July 1. Rand Group. International Prescription Drug Price Comparisons. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/bc582e25376d714694524a492fb15f36\/international-prescription-drug-price-comparisons.pdf."},{"issue":"6","key":"10.1016\/j.bbi.2024.10.006_b0495","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S1471-4906(03)00117-0","article-title":"Leukocyte\u2013endothelial-cell interactions in leukocyte transmigration and the inflammatory response","volume":"24","author":"Muller","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0500","unstructured":"Multifocal motor neuropathy - About the Disease - Genetic and Rare Diseases Information Center\u2014 rarediseases.info.nih.gov. (n.d.). https:\/\/rarediseases.info.nih.gov\/diseases\/11011\/ multifocal-motor-neuropathy\/. ([Accessed 11-09-2023])."},{"key":"10.1016\/j.bbi.2024.10.006_b0505","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s10072-020-04486-3","article-title":"The neurological manifestations of covid-19: a review article","volume":"41","author":"Niazkar","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbi.2024.10.006_b0510","doi-asserted-by":"crossref","unstructured":"Ofosu, F.A., Freedman, J., Semple, J.W., 2008, 5. Plasma-derived biological medicines used to promote haemostasis. Thrombosis and haemostasis, 99, 851-862. Retrieved from https:\/\/ pubmed.ncbi.nlm.nih.gov\/18449414\/ DOI: 10.1160\/TH07-10-0592.","DOI":"10.1160\/TH07-10-0592"},{"key":"10.1016\/j.bbi.2024.10.006_b0515","first-page":"336","article-title":"Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: a meta-analysis","volume":"30","author":"Olyaeemanesh","year":"2016","journal-title":"Med. J. Islam Repub. Iran"},{"key":"10.1016\/j.bbi.2024.10.006_bib804","unstructured":"\u201cPentaglobin\u00ae.\u201d Paviour, 2014, paviour.org\/human-igm-enriched-immunoglobulin\/."},{"key":"10.1016\/j.bbi.2024.10.006_b0520","doi-asserted-by":"crossref","unstructured":"Perez, E.E., Orange, J.S., Bonilla, F., Chinen, J., Chinn, I.K., Dorsey, M., Ballow, M., 2017, 3. Update on the use of immunoglobulin in human disease: A review of evidence. The Journal of allergy and clinical immunology, 139, S1-S46. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/ 28041678\/ DOI: 10.1016\/J.JACI.2016.09.023.","DOI":"10.1016\/j.jaci.2016.09.023"},{"key":"10.1016\/j.bbi.2024.10.006_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102468","article-title":"The anti-viral facet of anti-rheumatic drugs: lessons from covid-19","volume":"111","author":"Perricone","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bbi.2024.10.006_b0530","doi-asserted-by":"crossref","unstructured":"Peterson, P.K., Shepard, J., Macres, M., Schenck, C., Crosson, J., Rechtman, D., Lurie, N., 1990. A controlled trial of intravenous immunoglobulin g in chronic fatigue syndrome. The American Journal of Medicine, 89(5), 554-560. Retrieved from https:\/\/www.sciencedirect.com\/science\/ article\/pii\/000293439090172A DOI: 10.1016\/0002-9343(90)90172-A.","DOI":"10.1016\/0002-9343(90)90172-A"},{"issue":"1\u20132","key":"10.1016\/j.bbi.2024.10.006_b0535","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jneuroim.2010.08.023","article-title":"Ivig inhibits classical pathway activity and anti-gm1 igm-mediated complement deposition in mmn","volume":"229","author":"Piepers","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0540","unstructured":"Plasma Protein Therapeutics Association. (n.d.). Quality Standards of Excellence, Assurance, and Leadership (QSEAL). Retrieved April 7, 2024, from https:\/\/www.pptaglobal.org\/material\/quality-standards-of-excellence-assurance-and-leadership-qseal."},{"key":"10.1016\/j.bbi.2024.10.006_b0545","unstructured":"Plasma Protein Therapeutics Association (PPTA). \u201cDonate Plasma.\u201d PPTA Global. https:\/\/www.pptaglobal.org\/donate, Retrieved April 7, 2024."},{"key":"10.1016\/j.bbi.2024.10.006_b0550","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/infdis\/147.6.1090","article-title":"Antibody activity against pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans","volume":"147","author":"Pollack","year":"1983","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.bbi.2024.10.006_b0555","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s42399-020-00438-2","article-title":"Efficacy of plasmapheresis and immunoglobulin replacement therapy (ivig) on patients with covid-19","volume":"2","author":"Pourahmad","year":"2020","journal-title":"SN Comprehensive Clinical Medicine"},{"key":"10.1016\/j.bbi.2024.10.006_b0560","doi-asserted-by":"crossref","unstructured":"Rachid, R., Castells, M., Cunningham-Rundles, C., Bonilla, F.A., 2011. Association of anti-iga antibodies with adverse reactions to gamma globulin infusion. The Journal of allergy and clinical immunology, 128, 228. Retrieved from \/pmc\/articles\/PMC3129450\/https:\/\/www.ncbi.nlm.nih .gov\/pmc\/articles\/PMC3129450\/ DOI: 10.1016\/J.JACI.2011.01.061.","DOI":"10.1016\/j.jaci.2011.01.061"},{"issue":"1","key":"10.1016\/j.bbi.2024.10.006_b0565","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13054-022-04059-0","article-title":"Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study","volume":"26","author":"Rahmel","year":"2022","journal-title":"Crit. Care"},{"key":"10.1016\/j.bbi.2024.10.006_b0570","series-title":"Physical Medicine and Rehabilitation Clinics of North America","article-title":"Immunologic and autoimmune related sequelae of sars-cov-2 infection: Clinical symptoms and mechanisms of disease","author":"Ramasamy","year":"2023"},{"key":"10.1016\/j.bbi.2024.10.006_b0575","unstructured":"Recover-Autonomic Clinical Trial.\u201d Recover, Researching Covid to Enhance Recovery, trials.recovercovid.org\/autonomic. Accessed 6 Sept. 2024."},{"issue":"1\u20132","key":"10.1016\/j.bbi.2024.10.006_b0580","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.03.018","article-title":"Increased blood plasma concentrations of tgf-\u03b2 isoforms after treatment with intravenous immunoglobulins (ivig) in patients with multiple sclerosis","volume":"152","author":"Reinhold","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0585","doi-asserted-by":"crossref","unstructured":"Rungjirajittranon, T., Owattanapanich, W., 2019, 1. A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: A case report. Journal of Medical Case Reports, 13, 1-6. Retrieved from https:\/\/jmedicalcasereports.biomedcentral.com\/ articles\/10.1186\/s13256-018-1955-x DOI: 10.1186\/S13256-018-1955-X\/TABLES\/1.","DOI":"10.1186\/s13256-018-1955-x"},{"key":"10.1016\/j.bbi.2024.10.006_b0590","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00152193-200406000-00023","article-title":"How to administer a subcutaneous injection","volume":"34","author":"Rushing","year":"2004","journal-title":"Nursing"},{"key":"10.1016\/j.bbi.2024.10.006_b0595","doi-asserted-by":"crossref","unstructured":"Rutter, A., Luger, T.A., 2001, June. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. Journal of the American Academy of Dermatology, 44(6), 1010\u20131024. Retrieved from [QxMDMEDLINELink].","DOI":"10.1067\/mjd.2001.112325"},{"issue":"5","key":"10.1016\/j.bbi.2024.10.006_b0600","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/1744666X.2015.1029457","article-title":"Economic burden of common variable immunodeficiency: annual cost of disease","volume":"11","author":"Sadeghi","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0605","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/21645515.2019.1602434","article-title":"Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages","volume":"16","author":"Saha","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bbi.2024.10.006_b0610","doi-asserted-by":"crossref","unstructured":"Sakoulas, G., Geriak, M., Kullar, R., Greenwood, K.L., Habib, M., Vyas, A., Haddad, F., 2020. Intravenous immunoglobulin (ivig) significantly reduces respiratory morbidity in covid-19 pneumonia: a prospective randomized trial. medRxiv, 2020\u201307.","DOI":"10.1101\/2020.07.20.20157891"},{"key":"10.1016\/j.bbi.2024.10.006_bib803","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1365-2141.2001.02742.x","article-title":"Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy","volume":"113","author":"Sati","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.bbi.2024.10.006_b0615","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.842643","article-title":"Impact of hypogammaglobulinemia on the course of covid-19 in a non-intensive care setting: a single-center retrospective cohort study","volume":"13","author":"Scarpa","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0620","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1055\/s-0028-1113997","article-title":"Uber neue m\u00a8oglichkeiten intraven\u00a8oser gammaglobulin-\u00a8 applikation","volume":"87","author":"Schultze","year":"1962","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"7","key":"10.1016\/j.bbi.2024.10.006_b0625","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-\u03b1 and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2024.10.006_b0630","doi-asserted-by":"crossref","unstructured":"Singh-Grewal, D., Kemp, A., Wong, M., 2006, 8. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Archives of disease in childhood, 91, 651-654. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/16638785\/ DOI: 10.1136\/ADC.2005.078733.","DOI":"10.1136\/adc.2005.078733"},{"issue":"2","key":"10.1016\/j.bbi.2024.10.006_b0635","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-510X(02)00343-X","article-title":"The role of intravenous immunoglobulin in the treatment of multiple sclerosis","volume":"206","author":"Sorensen","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbi.2024.10.006_b0640","doi-asserted-by":"crossref","unstructured":"Sotzny, F., Blanco, J., Capelli, E., Castro-Marrero, J., Steiner, S., Murovska, M., European Network on ME\/CFS (EUROMENE), 2018. Myalgic encephalomyelitis\/chronic fatigue syndrome evidence for an autoimmune disease. Autoimmunity Reviews, 17(6), 601-609. (Epub 2018 Apr 7) DOI: 10.1016\/j.autrev.2018.01.009.","DOI":"10.1016\/j.autrev.2018.01.009"},{"issue":"3","key":"10.1016\/j.bbi.2024.10.006_b0645","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-b cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bbi.2024.10.006_b0650","doi-asserted-by":"crossref","unstructured":"Steinberger, B.A., Ford, S.M., Coleman, T.A., 2003, 6. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. American journal of hematology, 73, 97-100. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/ 12749010\/ DOI: 10.1002\/AJH.10325.","DOI":"10.1002\/ajh.10325"},{"key":"10.1016\/j.bbi.2024.10.006_b0655","doi-asserted-by":"crossref","unstructured":"Stokes, J., Maris, E.P., Gellis, S.S., 1944, 7. Chemical, clinical, and immunological studies on the products of human plasma fractionation. xi. the use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prophylaxis and treatment of measles. The Journal of clinical investigation, 23, 531-540. Retrieved from https:\/\/pubmed.ncbi.nlm.nih .gov\/16695129\/ DOI: 10.1172\/JCI101518.","DOI":"10.1172\/JCI101518"},{"issue":"8406","key":"10.1016\/j.bbi.2024.10.006_b0660","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor viii (antihaemophilic factor) by high-dose intravenous gammaglobulin","volume":"324","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2024.10.006_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107205","article-title":"Evaluating the effects of intravenous immunoglobulin (ivig) on the management of severe covid-19 cases: a randomized controlled trial","volume":"90","author":"Tabarsi","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbi.2024.10.006_b0670","doi-asserted-by":"crossref","unstructured":"Takahashi, K., Oharaseki, T., Yokouchi, Y., Hiruta, N., Naoe, S., 2010. Kawasaki disease as a systemic vasculitis in childhood. Annals of Vascular Diseases, 3, 173. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/ pmc\/articles\/PMC3595783\/ DOI: 10.3400\/AVD.SASVP01003.","DOI":"10.3400\/avd.sasvp01003"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.006_b0675","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archneur.1993.00540040069017","article-title":"Immunoglobulin g immunosuppression of multiple sclerosis: suppression of all three major lymphocyte subsets","volume":"50","author":"Tenser","year":"1993","journal-title":"Arch. Neurol."},{"issue":"22","key":"10.1016\/j.bbi.2024.10.006_b0680","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2023.8823","article-title":"Development of a definition of post-acute sequelae of sars-cov-2 infection","volume":"329","author":"Thaweethai","year":"2023","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.bbi.2024.10.006_b0685","unstructured":"Therapeutics, G., 2013. Gamastan \u00ae s\/d 2 solvent\/detergent treated. Retrieved from https:\/\/ www.fda.gov\/media\/86789\/download."},{"key":"10.1016\/j.bbi.2024.10.006_b0690","doi-asserted-by":"crossref","first-page":"1033651","DOI":"10.3389\/fimmu.2022.1033651","article-title":"February 02). Sec. viral immunology","volume":"13","author":"Thompson","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bbi.2024.10.006_b0695","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-3083.1994.tb03511.x","article-title":"Immunological abnormalities in patients with chronic fatigue syndrome","volume":"40","author":"Tirelli","year":"1994","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.bbi.2024.10.006_b0700","doi-asserted-by":"crossref","unstructured":"Toy, P., Gajic, O., Bacchetti, P., Looney, M.R., Gropper, M.A., Hubmayr, R., Matthay, M.A., 2012, 2. Transfusion-related acute lung injury: incidence and risk factors. Blood, 119, 1757-1767. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/22117051\/ DOI: 10.1182\/BLOOD-2011-08370932.","DOI":"10.1182\/blood-2011-08-370932"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.006_b0705","doi-asserted-by":"crossref","first-page":"pzac005","DOI":"10.1093\/ptj\/pzac005","article-title":"Chronic fatigue and postexertional malaise in people living with long covid: an observational study","volume":"102","author":"Twomey","year":"2022","journal-title":"Phys. Ther."},{"key":"10.1016\/j.bbi.2024.10.006_b0710","unstructured":"U.S. Food and Drug Administration. (n.d.). U.S. food and drug administration. Retrieved from https:\/\/ www.fda.gov\/postvaccines-blood-biologics\/approved-blood-products\/immune-globulins."},{"key":"10.1016\/j.bbi.2024.10.006_b0715","doi-asserted-by":"crossref","unstructured":"Uchida, Y., Kato, D., Adachi, K., Toyoda, T., Matsukawa, N., 2017, 12. Passively acquired thyroid autoantibodies from intravenous immunoglobulin in autoimmune encephalitis: Two case reports. Journal of the neurological sciences, 383, 116-117. Retrieved from https:\/\/pubmed.ncbi.nlm.nih .gov\/29246597\/ DOI: 10.1016\/J.JNS.2017.11.002.","DOI":"10.1016\/j.jns.2017.11.002"},{"key":"10.1016\/j.bbi.2024.10.006_b0720","unstructured":"US Department of Health and Human Services. (2018, October 24). Comparison of U.S. and international prices for top Medicare part B drugs by total expenditures. ASPE. https:\/\/aspe.hhs.gov\/reports\/comparison-us-international-prices-top-medicare-part-b-drugs-total-expenditures."},{"issue":"17","key":"10.1016\/j.bbi.2024.10.006_b0725","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in guillain\u2013barr\u00e9 syndrome","volume":"326","author":"Van der Mech\u00e9","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2024.10.006_b0730","doi-asserted-by":"crossref","unstructured":"Vlaar, A.P., Toy, P., Fung, M., Looney, M.R., Juffermans, N.P., Bux, J., Kleinman, S., 2019, 7. A consensus redefinition of transfusion-related acute lung injury. Transfusion, 59, 2465-2476. Retrieved from https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/trf.15311htmstps:\/\/ onlinelibrary.wiley.com\/doi\/abs\/10.1111\/trf.15311https:\/\/onlinelibrary.wiley.com\/ doi\/10.1111\/trf.15311 DOI: 10.1111\/TRF.15311.","DOI":"10.1111\/trf.15311"},{"key":"10.1016\/j.bbi.2024.10.006_b0735","doi-asserted-by":"crossref","unstructured":"Vollmer-Conna, U., Hickie, I., Hadzi-Pavlovic, D., Tymms, K., Wakefield, D., Dwyer, J., Lloyd, A., 1997. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. The American journal of medicine, 103 (1), 38\u201343.","DOI":"10.1016\/S0002-9343(97)90045-0"},{"key":"10.1016\/j.bbi.2024.10.006_b0740","doi-asserted-by":"crossref","unstructured":"Wan, Y., Ghosh, R., Cui, Z., 2004, 7. Separation of human serum albumin and human immunoglobulins using carrier phase ultrafiltration. Biotechnology progress, 20, 1103-1112. Retrieved from https:\/\/pubmed.ncbi.nlm.nih.gov\/15296436\/ DOI: 10.1021\/BP0343716.","DOI":"10.1021\/bp0343716"},{"issue":"124","key":"10.1016\/j.bbi.2024.10.006_b0745","article-title":"Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants","volume":"20","author":"Wang","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.bbi.2024.10.006_b0750","doi-asserted-by":"crossref","unstructured":"Wilson, C.S., Hoopes, E.M., Falk, A.C., Moore, D.J., 2022, 7. A human igm enriched immunoglobulin preparation, pentaglobin, reverses autoimmune diabetes without immune suppression in nod mice. Scientific Reports 2022 12:1, 12, 1-7. DOI: 10.1038\/s41598-022-15676-8.","DOI":"10.1038\/s41598-022-15676-8"},{"key":"10.1016\/j.bbi.2024.10.006_b0755","doi-asserted-by":"crossref","unstructured":"Winer, J., et al., 2014. An update in guillain-barr\u00e9 syndrome. Autoimmune diseases, 2014.","DOI":"10.1155\/2014\/793024"},{"key":"10.1016\/j.bbi.2024.10.006_b0760","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","article-title":"Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations","volume":"65","author":"Wolberg","year":"2000","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbi.2024.10.006_b0765","doi-asserted-by":"crossref","unstructured":"Wolfe, G.I., Sally Ward, E., de Haard, H., Ulrichts,P., Mozaffar, T., Pasnoor, M., Vidarsson, G., 2021. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis, Journal of the Neurological Sciences, Volume 430, 2021, 118074, ISSN 0022-510X, https:\/\/doi.org\/10.1016\/j.jns.2021.118074.","DOI":"10.1016\/j.jns.2021.118074"},{"key":"10.1016\/j.bbi.2024.10.006_b0770","doi-asserted-by":"crossref","unstructured":"Xiang, H., Cheng, X., Li, Y., Luo, W., Zhang, Q., Peng, W., 2021, Jul. Efficacy of ivig (intravenous immunoglobulin) for coronavirus disease 2019 (covid-19): A meta-analysis. International Immunopharmacology, 96, 107732. (Epub 2021 Apr 30) DOI: 10.1016\/j.intimp.2021.107732.","DOI":"10.1016\/j.intimp.2021.107732"},{"key":"10.1016\/j.bbi.2024.10.006_b0775","doi-asserted-by":"crossref","unstructured":"Xu, E., Xie, Y., Al-Aly, Z., 2022. Long-term neurologic outcomes of covid-19. Nature medicine, 28(11), 2406\u20132415.","DOI":"10.1038\/s41591-022-02001-z"},{"issue":"4","key":"10.1016\/j.bbi.2024.10.006_b0780","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0002-9440(10)65670-2","article-title":"Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases","volume":"153","author":"Xu","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.bbi.2024.10.006_b0785","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with sars-cov-2 pneumonia in wuhan, china: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.bbi.2024.10.006_b0790","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bbi.2024.10.006_b0795","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"Iv immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.bbi.2024.10.006_b0800","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"Iv immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159124006482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159124006482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T22:39:12Z","timestamp":1747867152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159124006482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":164,"alternative-id":["S0889159124006482"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2024.10.006","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}